Traws Pharma
TRAW
17 hedge funds and large institutions have $38.2M invested in Traws Pharma in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 10 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
23% less funds holding
Funds holding: 22 → 17 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
62% less capital invested
Capital invested by funds: $102M → $38.2M (-$63.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.4M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.79M |
| 3 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$2.84M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$1.89M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$947K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$25.6M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$5.19M |
| 3 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
-$4.73M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.85M |
| 5 |
JP Morgan Chase
New York
|
-$3.25M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$3.85M | -3 | Closed |
|
|
52
JP Morgan Chase
New York
| – | -$3.25M | -2 | Closed |
|
|
QF
53
QVT Financial
New York
| – | -$2.49M | -2 | Closed |
|
|
DCM
54
Driehaus Capital Management
Chicago,
Illinois
| – | -$2.06M | -1 | Closed |
|
|
LCG
55
Lisanti Capital Growth
New York
| – | -$1.55M | -1 | Closed |
|
|
WSA
56
Wall Street Associates
Lajolla,
California
| – | -$1.71M | -1 | Closed |
|
57
Wellington Management Group
Boston,
Massachusetts
| – | -$1M | -1 | Closed |
|
58
BlackRock
New York
| – | -$4K | – | – |
|
|
BG
59
BlackRock Group
London,
United Kingdom
| – | -$11K | – | – |
|
|
COPPSERS
60
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
| – | -$456K | – | – |
|
|
NTCOC
61
Northern Trust Company of Connecticut
Stamford,
Connecticut
| – | -$78K | – | – |
|
62
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$4K | – | – |
|
|
TC
63
TFS Capital
West Chester,
Pennsylvania
| – | -$683K | – | – |
|
64
HighTower Advisors
Chicago,
Illinois
| – | +$947K | +1 | New |
|
TRAW Hedge Fund Activity: Q4 2013 in Review
17 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2013, worth a combined $38.2M — down 62% from $102M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TRAW and 5 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 5 added.
The largest buyer was Fidelity Investments, adding an estimated $10.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $25.6M sold.
- 17 institutional investors held Traws Pharma (TRAW) as of Q4 2013, down from 22 in Q3 2013.
- Funds reported $38.2M of Traws Pharma stock for Q4 2013, down 62% quarter-over-quarter.
- 5 funds opened new Traws Pharma positions in Q4 2013 and 10 closed out, a net change of -5 holders.
- The largest Traws Pharma buyer in Q4 2013 was Fidelity Investments, an estimated $10.4M added.
- The largest Traws Pharma seller in Q4 2013 was Deerfield Management, an estimated $25.6M sold.
Based on aggregated 13F filings for Q4 2013.